查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591987

免疫抑制劑市場：按功能、藥物類別、給藥途徑和最終用戶分類 - 2025-2030 年全球預測

Immunosuppressant Drugs Market by Function (Autoimmune Diseases, Organ Transplant), Drug Class (Antiproliferative Agent, Calcineurin Inhibitor, mTOR Inhibitor), Route of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年免疫抑制劑市場價值為11.1億美元，預計到2024年將達到11.8億美元，複合年成長率為6.36%，到2030年預計將達到17.1億美元。

免疫抑制劑對於透過抑製或調節免疫系統來預防器官移植排斥和治療自體免疫疾病至關重要。這些藥物有多種類別，包括Calcineurin抑制劑、mTOR 抑制劑和單株抗體，適用於器官移植患者和患有類風濕性關節炎和狼瘡等自體免疫疾病的患者。器官移植的增加和對自體自體免疫疾病認知的提高推動了對免疫抑制劑的需求，確保了免疫抑制劑在現代醫學中的重要作用。推動市場的關鍵因素是目標疾病盛行率的上升、採用創新治療方法的先進醫療設施以及不斷增加的研究合作。由於醫療基礎設施的改善和移植數量的增加，亞太地區的新興市場提供了充滿希望的成長機會。然而，市場面臨高成本、潛在副作用、嚴格的監管核准和複雜的藥物開發流程等挑戰。由於醫生和患者謹慎採用，副作用和感染風險增加也阻礙了市場成長。個人化醫療等創新可以根據個人的基因特徵客製化免疫抑制治療，有可能改善患者的治療結果。最大限度地減少副作用並提高功效的新配方的研究和開發可能會成為未來成長的驅動力。公司可以透過投資與生物技術公司合作來研究下一代免疫抑制劑來利用這些機會。此外，關注患者教育和意識計劃可以提高市場接受度。策略性資助以及與研究機構的合作可以加速這一領域的突破。競爭激烈的市場需要不斷適應新的科學發現和監管變化。總體而言，雖然有希望的進展和市場需求帶來了巨大的機遇，但仔細了解監管環境並解決與藥物耐受性相關的問題對於市場的持續成長仍然至關重要。

主要市場統計
基準年[2023] 11.1億美元
預測年份 [2024] 11.8億美元
預測年份 [2030] 17.1億美元
複合年成長率（%） 6.36%

市場動態：揭示快速發展的免疫抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變免疫抑制劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於生活方式的改變，自體免疫疾病的盛行率增加
    • 肺、腎、肝、胰等器官移植數量增加
    • 改善組織工程和器官移植
  • 市場限制因素
    • 複雜的監管流程
  • 市場機會
    • 新藥物療法的開發
    • 免疫腫瘤學的最新進展和監管核准
  • 市場挑戰
    • 個體化免疫抑制治療相關的併發症

波特五力：駕馭免疫抑制劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫抑制劑市場的外部影響

外部宏觀環境因素在塑造免疫抑制劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解免疫抑制劑市場的競爭狀況

免疫抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣免疫抑制劑市場供應商的績效評估

FPNV定位矩陣是評估免疫抑制劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製免疫抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對免疫抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於生活方式的改變，自體免疫疾病的盛行率增加
      • 肺、腎、肝、胰等器官移植手術呈上升趨勢。
      • 組織工程和器官移植的進展
    • 抑制因素
      • 複雜的監管流程
    • 機會
      • 新藥物療法的開發
      • 免疫腫瘤學的最新進展和監管核准
    • 任務
      • 與個人化免疫抑制治療相關的併發症
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章免疫抑制劑市場：依功能分類

  • 自體免疫疾病
    • 局部自體免疫疾病
    • 系統性自體免疫疾病
  • 器官移植

第7章依藥物類別分類的免疫抑制劑市場

  • 抗增殖劑
  • Calcineurin抑制劑
  • mTOR抑制劑
  • 類固醇

第8章免疫抑制劑市場：依給藥途徑

  • 靜脈
  • 口服

第9章免疫抑制劑市場：依最終用戶分類

  • 診所
  • 醫院
  • 療養院
  • 器官移植中心
  • 復健中心

第10章美洲免疫抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太免疫抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲免疫抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sebela Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
Product Code: MRR-434CCDA051EC

The Immunosuppressant Drugs Market was valued at USD 1.11 billion in 2023, expected to reach USD 1.18 billion in 2024, and is projected to grow at a CAGR of 6.36%, to USD 1.71 billion by 2030.

Immunosuppressant drugs are crucial for preventing organ transplant rejection and treating autoimmune diseases by suppressing or modulating the immune system. The scope of these drugs includes various classes, such as calcineurin inhibitors, mTOR inhibitors, and monoclonal antibodies, catering to organ transplant patients and individuals with autoimmune conditions like rheumatoid arthritis and lupus. The necessity for immunosuppressants stems from the increasing incidence of organ transplants and a growing awareness of autoimmune diseases, ensuring their vital role in modern medicine. A significant factor driving the market is the rising prevalence of target diseases, advanced healthcare facilities adopting innovative treatments, and increased research collaborations. Emerging markets in Asia-Pacific, due to improving healthcare infrastructure and an increasing number of transplants, offer promising growth opportunities. However, the market faces challenges, including high costs, potential side effects, stringent regulatory approvals, and the complex drug development process. Adverse reactions and increased infection risk also impede market growth due to cautious adoption among physicians and patients. Innovations such as personalized medicine, which tailors immunosuppressive therapy to individual genetic profiles, present potential for improved patient outcomes. R&D efforts into novel drug formulations that minimize side effects and enhance efficacy will likely drive future growth. Companies can capitalize on these opportunities by investing in collaborations with biotechnology firms to explore next-generation immunosuppressants. Additionally, focusing on patient education and awareness programs can stimulate market acceptance. Strategic funding and partnerships with research institutions could accelerate breakthroughs in this domain. The competitive nature of the market demands constant adaptation to emerging scientific discoveries and regulatory changes. Overall, while promising advancements and market needs present substantial opportunities, careful navigation of regulatory landscapes and addressing drug tolerability issues remain crucial for sustained market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 1.11 billion
Estimated Year [2024] USD 1.18 billion
Forecast Year [2030] USD 1.71 billion
CAGR (%) 6.36%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunosuppressant Drugs Market

The Immunosuppressant Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of autoimmune disease due to changing lifestyles
    • Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
    • Improvements in tissue engineering and organ transplantations
  • Market Restraints
    • Complicated regulatory processes
  • Market Opportunities
    • Development of novel drug therapies
    • Recent advances in immuno-oncology and regulatory approvals
  • Market Challenges
    • Complications associated with the personalizing immunosuppressive therapy

Porter's Five Forces: A Strategic Tool for Navigating the Immunosuppressant Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunosuppressant Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunosuppressant Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunosuppressant Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunosuppressant Drugs Market

A detailed market share analysis in the Immunosuppressant Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunosuppressant Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunosuppressant Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunosuppressant Drugs Market

A strategic analysis of the Immunosuppressant Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunosuppressant Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Sebela Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Immunosuppressant Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Function, market is studied across Autoimmune Diseases and Organ Transplant. The Autoimmune Diseases is further studied across Localized Autoimmune Disease and Systemic Autoimmune Disease.
  • Based on Drug Class, market is studied across Antiproliferative Agent, Calcineurin Inhibitor, mTOR Inhibitor, and Steroid.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Clinic, Hospital, Old Age Home, Organ Transplant Center, and Rehabilitation Center.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune disease due to changing lifestyles
      • 5.1.1.2. Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
      • 5.1.1.3. Improvements in tissue engineering and organ transplantations
    • 5.1.2. Restraints
      • 5.1.2.1. Complicated regulatory processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel drug therapies
      • 5.1.3.2. Recent advances in immuno-oncology and regulatory approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with the personalizing immunosuppressive therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immunosuppressant Drugs Market, by Function

  • 6.1. Introduction
  • 6.2. Autoimmune Diseases
    • 6.2.1. Localized Autoimmune Disease
    • 6.2.2. Systemic Autoimmune Disease
  • 6.3. Organ Transplant

7. Immunosuppressant Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antiproliferative Agent
  • 7.3. Calcineurin Inhibitor
  • 7.4. mTOR Inhibitor
  • 7.5. Steroid

8. Immunosuppressant Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Immunosuppressant Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Old Age Home
  • 9.5. Organ Transplant Center
  • 9.6. Rehabilitation Center

10. Americas Immunosuppressant Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Immunosuppressant Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Immunosuppressant Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. Cadila Healthcare Ltd.
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. GlaxoSmithKline PLC
  • 7. Glenmark Pharmaceuticals Limited
  • 8. Intas Pharmaceuticals Ltd.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Sanofi S.A.
  • 12. Sebela Pharmaceuticals
  • 13. Teva Pharmaceuticals Industries Ltd.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOSUPPRESSANT DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIPROLIFERATIVE AGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CALCINEURIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY OLD AGE HOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023